Histidine for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Histidine for Health & Longevity

Created on 09/20/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

An essential amino acid from everyday protein foods. The strongest human signal is in eczema, where rash severity fell within one to three months. One controlled study in women with excess body fat reported lower fat mass and better insulin handling. Everything else rests on single studies or animal work. Tolerance appears good to about eight grams a day. (Full Review)

Protocol

Standard supplemental dose
4–4.5 g/day L-histidine
The dose used in the metabolic-syndrome, adult eczema and rheumatoid-arthritis trials, and the dose the benefit literature is built on.
Upper bound
8 g/day
Human no-observed-adverse-effect level; 12 g/day is the lowest-observed-adverse-effect level. No efficacy trial has dosed above 4.5 g/day.
Single versus split dosing
Two 2 g doses with meals
Split dosing is standard: it keeps each bolus small enough to limit gastrointestinal upset and spreads the short plasma peak across the day.
Time to effect
Skin severity, adults
4 weeks
Skin severity scores moved by four weeks in the adult eczema trial.
Skin severity, children
12 weeks
The paediatric eczema pilot measured its severity endpoint at twelve weeks.
Metabolic endpoints
12 weeks
Body composition, glycaemic and inflammatory outcomes were measured only at twelve weeks, so metabolic endpoints need a full quarter.

Benefits

Contraindications
  • Decompensated liver disease or cirrhosis (Child-Pugh Class B or C)
  • Any history of hepatic encephalopathy
  • Chronic kidney disease stage 4 or worse (eGFR below 30 mL/min/1.73 m²) outside specialist supervision
  • Untreated folate deficiency (serum folate below 3 ng/mL) until repleted
  • Systemic mastocytosis or physician-diagnosed histamine intolerance
  • Pregnancy and lactation
  • Children and adolescents, outside the 0.8 g/day eczema protocol under paediatric supervision
Key Interactions
  • Prescription antifolates (methotrexate, trimethoprim, pyrimethamine)
  • Prescription histamine-pathway drugs (isoniazid, metoclopramide, famotidine)
  • Over-the-counter antihistamines (cetirizine, loratadine, diphenhydramine)
  • Over-the-counter analgesics and acid suppressants (aspirin, ibuprofen, omeprazole)
  • Zinc and copper supplements
  • Metal-binding supplements with additive effect (high-dose iron, calcium carbonate, phytate-rich fibre, alpha-lipoic acid)
  • β-Alanine and carnosine supplements (additive on the same pathway)
  • Other amino-acid and protein supplements (branched-chain amino acids, essential amino acid blends, whey)
  • Other interventions (low-histamine elimination diets, high-protein or carnivore diets)

Risk & Side Effects

  • Medium: Falling serum zinc and ferritin at high doses; rising blood urea nitrogen and liver enzymes
  • Low: Cognitive and eating disturbance at very high intakes; gastrointestinal upset at gram doses
  • Speculative: Ammonia rise and branched-chain amino acid fall in liver disease; histamine-mediated flushing, headache and itch; diverted gut metabolism to imidazole propionate

Monitoring

Marker Target Why
Plasma histidine 70–110 µmol/L Confirms the deficiency state the benefit trials targeted
Serum zinc 90–120 µg/dL The proposed tolerance marker for histidine; falls at high intakes
Ferritin 50–150 ng/mL (men), 30–100 ng/mL (women) Iron stores drifted down at 12 g/day versus 4 g/day
Serum folate Above 10 ng/mL Histidine catabolism consumes tetrahydrofolate, the active folate form
Blood urea nitrogen 10–16 mg/dL Rose with both dose and duration in the graded-dose safety study
Aspartate and alanine aminotransferase 10–26 U/L Aspartate aminotransferase rose at 16 g/day
HOMA-IR Below 1.5 The primary metabolic endpoint that moved in the supplementation trial
High-sensitivity C-reactive protein Below 1.0 mg/L Tracks the inflammatory endpoint claimed for histidine
Severity score (SCORing Atopic Dermatitis or Eczema Area and Severity Index) Reduction from the individual's own baseline; no population target exists The endpoint that moved fastest and most convincingly in trials

Cadence: At or below 4 g/day, serum zinc, blood urea nitrogen and liver enzymes are rechecked at 12 weeks, then every 6–12 months. Above 4 g/day, the first recheck moves forward to 8 weeks, repeating at 6 months and then every 6–12 months while use continues.

Qualitative Assessment

  • Skin dryness, itch intensity and the amount of topical corticosteroid actually used per week
  • Flushing, headache, nasal congestion or reflux, the pattern expected if histamine load is the problem
  • Daytime alertness and time to fall asleep, given histamine's wake-promoting role
  • Appetite and eating pattern, one of the reported effects and one of the reported harms at excess
  • Digestive tolerance of each dose, especially in the first four weeks of titration
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.